Royalty Pharma PLC - CL

Forecast & Rating8 analysts currently cover Royalty Pharma PLC - CL, with about 87.5% giving a positive rating — meaning they expect the stock to rise. The average price target is $64.75, about 5.6% upside from the current price of $61.31. Price targets are fairly clustered, pointing to relatively aligned views. Historically, about 13.3% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Royalty Pharma PLC - CL closely still see room for the stock to rise. Data as of Aug 12, 2026; for reference only and not investment advice.